Menu Search
Equities

Wai Chun Bio Technology Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
660:HKG.HS

Wai Chun Bio Technology Ltd

Actions
  • Price (HKD)0.26
  • Today's Change0.00 / 0.00%
  • Shares traded20.00k
  • 1 Year change+256.16%
  • Beta0.1355
Data delayed at least 15 minutes, as of Feb 13 2026 02:57 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Wai Chun Bio-Technology Ltd is a Hong Kong-based investment holding company principally engaged in the manufacture and sale of modified starch. Together with its subsidiaries, the Company is principally involved in the manufacture and sale of modified starch and other biochemical products, , such as biochemical refined oil products. In addition, the Company is also involved in the trading of electronic parts, components and electrical appliances.

  • Revenue in HKD (TTM)377.17m
  • Net income in HKD-14.62m
  • Incorporated--
  • Employees61.00
  • Location
    Wai Chun Bio Technology Ltd13/F, Admiralty Centre, Tower II18 Harcourt RoadAdmiralty Hong KongHKG
  • Phone+852 31029989
  • Fax+852 31028939
  • Websitehttps://www.0660.hk
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.